HONG KONG/BEIJING (Reuters) – Chinese firm Tibet Rhodiola Pharma holding <600211.SS> said on Wednesday that it has obtained non-exclusive right to develop, manufacture, import or commercialize Russia’s COVID-19 vaccine, Sputnik V, in mainland China, Hong Kong, Macau and Taiwan.
The Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, Russia’s sovereign wealth fund said earlier, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.
(Reporting by Meg Shen and Roxanne Liu, editing by Louise Heavens)
